The only significant difference by 10 mM PipFcB compared to the solvent control was observed for CD107a expression on CARTs stimulated with primary CLL cells (PipFcB 10 μM vs. DMSO 50% ± 6% vs. 29% ± 3%, p < 0.01; Figure 6D). Here, LAMP1 is linked to B-cell chronic lymphocytic leukemia.